Pulmonary function in heterozygotes for alpha1-antitrypsin deficiency: A case control study

A (Sonia) Buist, G. J. Sexton, A. M H Azzam, B. E. Adams

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In this paper we present the initial cross-sectional data from a prospective study of lung aging in heterozygotes for α1-antitrypsin deficiency. Using a case-control design, our cases included 37 heterozygotes for α1-antitrypsin deficiency, protease inhibitor phenotypes MZ and MS, selected because they were parents of children with homozygous α1-antitrypsin deficiency identified in a statewide newborn screening program between 1971 and 1974. All of the heterozygotes were less than 40 yr of age. Our control subjects were selected from a random sample of a working population participating in a longitudinal study of lung aging, using a 2:1 match of control subjects to cases, matching age, sex, ethnic origin, and smoking. Using a respiratory symptom questionnaire, spirometry, and the single-breath N2 test, we found no significant difference between heterozygotes and control subjects in terms of respiratory symptoms or pulmonary function data. We conclude that to 40 yr of age, the heterozygous phenotype (Pi MZ and MS) is not a risk factor for impairment of pulmonary function.

Original languageEnglish (US)
Pages (from-to)759-766
Number of pages8
JournalAmerican Review of Respiratory Disease
Volume120
Issue number4
StatePublished - 1979

Fingerprint

Heterozygote
Case-Control Studies
Lung
Phenotype
Breath Tests
Spirometry
Protease Inhibitors
Longitudinal Studies
Parents
Smoking
Newborn Infant
Prospective Studies
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary function in heterozygotes for alpha1-antitrypsin deficiency : A case control study. / Buist, A (Sonia); Sexton, G. J.; Azzam, A. M H; Adams, B. E.

In: American Review of Respiratory Disease, Vol. 120, No. 4, 1979, p. 759-766.

Research output: Contribution to journalArticle

@article{af1a362acf784b158ae066589e2b660e,
title = "Pulmonary function in heterozygotes for alpha1-antitrypsin deficiency: A case control study",
abstract = "In this paper we present the initial cross-sectional data from a prospective study of lung aging in heterozygotes for α1-antitrypsin deficiency. Using a case-control design, our cases included 37 heterozygotes for α1-antitrypsin deficiency, protease inhibitor phenotypes MZ and MS, selected because they were parents of children with homozygous α1-antitrypsin deficiency identified in a statewide newborn screening program between 1971 and 1974. All of the heterozygotes were less than 40 yr of age. Our control subjects were selected from a random sample of a working population participating in a longitudinal study of lung aging, using a 2:1 match of control subjects to cases, matching age, sex, ethnic origin, and smoking. Using a respiratory symptom questionnaire, spirometry, and the single-breath N2 test, we found no significant difference between heterozygotes and control subjects in terms of respiratory symptoms or pulmonary function data. We conclude that to 40 yr of age, the heterozygous phenotype (Pi MZ and MS) is not a risk factor for impairment of pulmonary function.",
author = "Buist, {A (Sonia)} and Sexton, {G. J.} and Azzam, {A. M H} and Adams, {B. E.}",
year = "1979",
language = "English (US)",
volume = "120",
pages = "759--766",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - Pulmonary function in heterozygotes for alpha1-antitrypsin deficiency

T2 - A case control study

AU - Buist, A (Sonia)

AU - Sexton, G. J.

AU - Azzam, A. M H

AU - Adams, B. E.

PY - 1979

Y1 - 1979

N2 - In this paper we present the initial cross-sectional data from a prospective study of lung aging in heterozygotes for α1-antitrypsin deficiency. Using a case-control design, our cases included 37 heterozygotes for α1-antitrypsin deficiency, protease inhibitor phenotypes MZ and MS, selected because they were parents of children with homozygous α1-antitrypsin deficiency identified in a statewide newborn screening program between 1971 and 1974. All of the heterozygotes were less than 40 yr of age. Our control subjects were selected from a random sample of a working population participating in a longitudinal study of lung aging, using a 2:1 match of control subjects to cases, matching age, sex, ethnic origin, and smoking. Using a respiratory symptom questionnaire, spirometry, and the single-breath N2 test, we found no significant difference between heterozygotes and control subjects in terms of respiratory symptoms or pulmonary function data. We conclude that to 40 yr of age, the heterozygous phenotype (Pi MZ and MS) is not a risk factor for impairment of pulmonary function.

AB - In this paper we present the initial cross-sectional data from a prospective study of lung aging in heterozygotes for α1-antitrypsin deficiency. Using a case-control design, our cases included 37 heterozygotes for α1-antitrypsin deficiency, protease inhibitor phenotypes MZ and MS, selected because they were parents of children with homozygous α1-antitrypsin deficiency identified in a statewide newborn screening program between 1971 and 1974. All of the heterozygotes were less than 40 yr of age. Our control subjects were selected from a random sample of a working population participating in a longitudinal study of lung aging, using a 2:1 match of control subjects to cases, matching age, sex, ethnic origin, and smoking. Using a respiratory symptom questionnaire, spirometry, and the single-breath N2 test, we found no significant difference between heterozygotes and control subjects in terms of respiratory symptoms or pulmonary function data. We conclude that to 40 yr of age, the heterozygous phenotype (Pi MZ and MS) is not a risk factor for impairment of pulmonary function.

UR - http://www.scopus.com/inward/record.url?scp=0018630770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018630770&partnerID=8YFLogxK

M3 - Article

C2 - 315737

AN - SCOPUS:0018630770

VL - 120

SP - 759

EP - 766

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 4

ER -